Perineologic, a subsidiary of Corbin Clinical Resources, Inc., today announced the appointment of Evan Brasington as Chief Commercial Officer. In this role, Mr. Brasington will be a member of the executive leadership team and will lead the company’s commercial strategy including operations, marketing, sales, and distribution of the PrecisionPoint™ Transperineal Access System, the only FDA cleared, CE marked, Class ll medical device for performing freehand transperineal prostate cancer biopsies.
For the past 30 years, screening for prostate-specific antigen (PSA) levels has been the gold standard for screening of prostate cancer. When high levels are found, physicians typically turn to a diagnostic biopsy using a transrectal route. However, a Maryland urologist has developed a different approach through the perineum, the strip of skin between the rectum and scrotum that is safer and more effective.